Abstract
In a retrospective study the postoperative time courses of CEA in colorectal cancer patients with recurrent disease were analysed. In 87/114 cases with increasing concentrations of circulating CEA under close follow-up a linear relationship between log CEA and time could be established during disease recurrence. The individual doubling times of the serum CEA concentration in the log CEA period were calculated and found to cover distinct ranges dependent on the diagnosis of disease recurrence. The CEA doubling times concomitant with local recurrence or second primary carcinomas ranged from 142 to 868 days, visceral metastasis other than liver metastasis from 47 to 231 days and liver metastasis from 10 to 102 days. Patients with bone metastases exhibited CEA doubling times of 54-60 days and a patient with brain metastasis had a CEA doubling time of 598 days. The CEA doubling times of patients with liver metastasis and no further treatment, correlated well with the time of survival after the initial CEA increase of the log CEA phase (r = 0.870, n = 33). The mean survival expressed in multiples of the individual CEA doubling times was 7.0 +/- 1.8. Patients with liver metastasis who underwent various treatments of recurrent disease had a distinctly longer mean survival of 17.4 +/- 9.4 CEA doubling times (P less than 0.001). CEA doubling times can be used as a potential method to assess the efficacy of various treatments.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Johnson P. J., Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst. 1980 Jun;64(6):1329–1332. doi: 10.1093/jnci/64.6.1329. [DOI] [PubMed] [Google Scholar]
- Raghavan D., Gibbs J., Nogueira Costa R., Kohn J., Orr A. H., Barrett A., Peckham M. J. The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. Br J Cancer Suppl. 1980 Apr;4:191–194. [PMC free article] [PubMed] [Google Scholar]
- Staab H. J., Anderer F. A., Stumpf E., Fischer R. Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract? Br J Cancer. 1980 Jul;42(1):26–33. doi: 10.1038/bjc.1980.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Staab H. J., Anderer F. A., Stumpf E., Fischer R. Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg. 1978 Sep;136(3):322–327. doi: 10.1016/0002-9610(78)90285-4. [DOI] [PubMed] [Google Scholar]
- Steele G., Jr, Zamcheck N., Wilson R., Mayer R., Lokich J., Rau P., Maltz J. Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg. 1980 Apr;139(4):544–548. doi: 10.1016/0002-9610(80)90335-9. [DOI] [PubMed] [Google Scholar]
- Toth C. A., Thomas P., Broitman S. A., Zamcheck N. A new Kupffer cell receptor mediating plasma clearance of carcinoembryonic antigen by the rat. Biochem J. 1982 May 15;204(2):377–381. doi: 10.1042/bj2040377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wood C. B., Ratcliffe J. G., Burt R. W., Malcolm A. J., Blumgart L. H. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg. 1980 Jan;67(1):46–48. doi: 10.1002/bjs.1800670114. [DOI] [PubMed] [Google Scholar]